Celltrion Archives | Be Korea-savvy
Celltrion Eyes Emergency Authorization for COVID-19 Treatment Next Month

Celltrion Eyes Emergency Authorization for COVID-19 Treatment Next Month

SEOUL, Nov. 18 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s coronavirus treatment is likely to file for emergency authorization use from local drug authorities next month, the company’s chief said Wednesday. CT-P59, anti-COVID-19 monoclonal antibody treatment, is currently undergoing a phase two clinical trial locally after successfully completing a phase one clinical trial [...]

Celltrion’s COVID-19 Treatment Kills Virus Within 4-5 Days: Chief

Celltrion’s COVID-19 Treatment Kills Virus Within 4-5 Days: Chief

SEOUL, Nov. 11 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s COVID-19 treatment kills the coronavirus within 4-5 days, effectively protecting patients with mild symptoms from developing a severe case, the company’s chief said Wednesday. Celltrion Group Chairman Seo Jung-jin said the first stage trial of CT-P59, anti-COVID-19 monoclonal antibody treatment, shortened the recovery [...]

Celltrion Inks Supply Agreement for COVID-19 Test Kit in U.S.

Celltrion Inks Supply Agreement for COVID-19 Test Kit in U.S.

SEOUL, Nov. 2 (Korea Bizwire) — South Korean biopharmaceutical giant Celltrion Inc. said Monday it has signed an agreement worth 210 billion won (US$185 million) to supply a diagnostic kit for the novel coronavirus in the United States. Under the agreement, Celltrion’s rapid antigen kit, Sampinute, will be distributed by Prime Healthcare Distributors in the [...]

Celltrion to Conduct Additional Phase 1 Trial for Coronavirus Treatment

Celltrion to Conduct Additional Phase 1 Trial for Coronavirus Treatment

SEOUL, Aug. 26 (Korea Bizwire) — Celltrion Inc., a leading pharmaceutical firm in South Korea, said Wednesday that it will conduct an additional phase one clinical trial of its coronavirus treatment on patients. Celltrion’s CT-P59 will be administered to nine COVID-19 patients with mild symptoms to evaluate the safety and efficacy of the antiviral antibody [...]

S. Korea Approves Phase 1 Trials for Celltrion’s COVID-19 Treatment Substance

S. Korea Approves Phase 1 Trials for Celltrion’s COVID-19 Treatment Substance

SEOUL, July 17 (Korea Bizwire) — South Korea approved phase one clinical trials for Celltrion Inc.’s coronavirus antibody treatment substance, the country’s drug safety agency said Friday. The move to test CT-P59 marks the first time that a locally made genetic recombination antibody treatment material has been given the green light to be used on [...]